DS
OREX

David Shaw’s Orexigen Therapeutics, Inc. OREX Stock Holding History

David Shaw’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-2,229
Closed -$38K – 4115
2015
Q4 		$38K Sell
2,229
-7,545
-77% -$180K ﹤0.01% 3728
2015
Q3 		$206K Sell
9,774
-14,191
-59% -$486K ﹤0.01% 3489
2015
Q2 		$1.19M Sell
23,965
-58,291
-71% -$3.48M ﹤0.01% 2570
2015
Q1 		$6.44M Buy
82,256
+8,574
+12% +$532K 0.01% 1221
2014
Q4 		$4.46M Sell
73,682
-28,054
-28% -$1.41M 0.01% 1662
2014
Q3 		$4.33M Buy
101,736
+16,505
+19% +$886K 0.01% 1668
2014
Q2 		$5.27M Buy
85,231
+13,122
+18% +$763K 0.01% 1581
2014
Q1 		$4.69M Sell
72,109
-82,709
-53% -$5.59M 0.01% 1647
2013
Q4 		$8.72M Buy
154,818
+14,927
+11% +$839K 0.01% 1249
2013
Q3 		$8.59M Buy
139,891
+463
+0.3% +$31.4K 0.01% 1142
2013
Q2 		$8.16M Buy
+139,428
New +$8.58M 0.02% 1004

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
SC
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

David Shaw's OREX Position: Q1 2016 in Review

David Shaw sold out of Orexigen Therapeutics, Inc. (OREX) in Q1 2016, closing a stake of 2,229 shares — an estimated $38K sold.

David Shaw first reported a position in OREX in Q2 2013 and held it in 11 quarters. The position peaked at $8.72M in Q4 2013. 104 funds tracked by Wall St. Rank hold OREX as of Q1 2016.

  • David Shaw reported no remaining Orexigen Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
  • David Shaw sold 2,229 Orexigen Therapeutics, Inc. shares in Q1 2016, an estimated $38K.
  • David Shaw first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 11 quarters.
  • David Shaw's Orexigen Therapeutics, Inc. position peaked at $8.72M in Q4 2013.
  • 104 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q1 2016.

Based on D.E. Shaw & Co's 13F filing for Q1 2016, filed 16 May 2016.